SG11201802754XA - Blood preparation and profiling - Google Patents
Blood preparation and profilingInfo
- Publication number
- SG11201802754XA SG11201802754XA SG11201802754XA SG11201802754XA SG11201802754XA SG 11201802754X A SG11201802754X A SG 11201802754XA SG 11201802754X A SG11201802754X A SG 11201802754XA SG 11201802754X A SG11201802754X A SG 11201802754XA SG 11201802754X A SG11201802754X A SG 11201802754XA
- Authority
- SG
- Singapore
- Prior art keywords
- profiling
- blood preparation
- blood
- preparation
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5002—Partitioning blood components
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5406—IL-4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5409—IL-5
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5412—IL-6
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5421—IL-8
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5428—IL-10
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5434—IL-12
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/545—IL-1
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/555—Interferons [IFN]
- G01N2333/57—IFN-gamma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2015904075A AU2015904075A0 (en) | 2015-10-07 | Blood preparation and profiling | |
PCT/AU2016/000341 WO2017059477A1 (en) | 2015-10-07 | 2016-10-06 | Blood preparation and profiling |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201802754XA true SG11201802754XA (en) | 2018-05-30 |
Family
ID=58487130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201802754XA SG11201802754XA (en) | 2015-10-07 | 2016-10-06 | Blood preparation and profiling |
Country Status (10)
Country | Link |
---|---|
US (2) | US11243218B2 (en) |
EP (2) | EP4009047A1 (en) |
JP (3) | JP6824994B2 (en) |
KR (1) | KR102632490B1 (en) |
CN (2) | CN114019171A (en) |
AU (1) | AU2016334875B2 (en) |
CA (1) | CA3001154C (en) |
HK (1) | HK1258470A1 (en) |
SG (1) | SG11201802754XA (en) |
WO (1) | WO2017059477A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108883133A (en) | 2015-12-22 | 2018-11-23 | 善威生物私人有限公司 | Use the treatment method of red blood cell |
AU2017379367B2 (en) | 2016-12-20 | 2023-12-07 | Sangui Bio Pty. Ltd | Blood profiling with protease inhibitors |
CN108715833B (en) * | 2018-06-01 | 2021-09-14 | 天晴干细胞股份有限公司 | Preparation method of microsphere loaded with platelet lysate |
WO2022192429A1 (en) * | 2021-03-10 | 2022-09-15 | Terasaki Insutitute For Biomedical Innovation | Constructs comprising fibrin or other blood products for meat cultivation and other applications |
CN114081899A (en) * | 2021-11-02 | 2022-02-25 | 四川大学华西医院 | Preparation method of leukocyte-rich and platelet-rich plasma |
WO2024010763A1 (en) * | 2022-07-07 | 2024-01-11 | Russell Biotech, Inc. | Preparation of platelet free mononuclear cells |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4931276A (en) | 1987-10-30 | 1990-06-05 | Franco Robert S | Method for introducing desired agents into red blood cells |
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
WO1992005801A1 (en) | 1990-10-04 | 1992-04-16 | University Of Virginia Alumni Patents Foundation | Primate erythrocyte bound monoclonal antibody heteropolymers |
FR2778851B1 (en) | 1998-05-19 | 2002-07-26 | Aetsrn | COMPOSITION BASED ON CYSTEINE PROTEASE INHIBITORS FOR DELAYING SENESCENCE, SELF-DESTRUCTION AND HEMOLYSIS OF ERYTHROCYTES |
US8431117B2 (en) | 1999-08-30 | 2013-04-30 | David S Terman | Sickled erythrocytes with anti-tumor agents induce tumor vaso-occlusion and tumoricidal effects |
MXPA03000765A (en) | 2000-07-24 | 2004-05-21 | Gendel Ltd | Polypeptide delivery ii-2. |
ES2498369T3 (en) | 2002-04-16 | 2014-09-24 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | A marker to measure liver cirrhosis |
US7501286B2 (en) | 2002-08-14 | 2009-03-10 | President And Fellows Of Harvard College | Absolute quantification of proteins and modified forms thereof by multistage mass spectrometry |
US7276382B2 (en) * | 2003-10-02 | 2007-10-02 | Noboru Horiguchi | Blood testing method |
GB0325483D0 (en) | 2003-10-31 | 2003-12-03 | Plasmacute As | Assay |
US20080095749A1 (en) | 2004-03-22 | 2008-04-24 | Sudeepta Aggarwal | Mesenchymal stem cells and uses therefor |
US7378054B2 (en) | 2004-04-16 | 2008-05-27 | Savvipharm Inc | Specimen collecting, processing and analytical assembly |
US20060166223A1 (en) | 2005-01-26 | 2006-07-27 | Reed Michael W | DNA purification and analysis on nanoengineered surfaces |
EP1875248A2 (en) | 2005-03-29 | 2008-01-09 | Inverness Medical Switzerland GmbH | Device and method of monitoring a patient |
US20100184049A1 (en) | 2007-04-27 | 2010-07-22 | Steve Goodison | Glycoprotein Profiling of Bladder Cancer |
FR2919804B1 (en) | 2007-08-08 | 2010-08-27 | Erytech Pharma | COMPOSITION AND ANTI-TUMOR THERAPEUTIC VACCINE |
WO2009110873A2 (en) | 2007-12-05 | 2009-09-11 | The Gov. Of The Usa, As Represented By The Secretary Dept. Of Health & Human Services | Improved viral protein quantification and vaccine quality control therewith |
CN102037355A (en) | 2008-03-04 | 2011-04-27 | 里奇诊断学股份有限公司 | Diagnosing and monitoring depression disorders based on multiple biomarker panels |
JP5748654B2 (en) | 2008-05-06 | 2015-07-15 | オカタ セラピューティクス, インコーポレイテッド | Method for producing enucleated red blood cells derived from pluripotent stem cells |
JP2012530133A (en) | 2009-06-16 | 2012-11-29 | ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | Methods for improving side effects associated with transfusion of red blood cells over time |
CA2766250C (en) * | 2009-06-30 | 2018-08-14 | Kaneka Corporation | Blood component separation system and separation material |
EP2464966A1 (en) | 2009-08-13 | 2012-06-20 | Basf Se | Means and methods for diagnosingthyroid disorders |
US20130202625A1 (en) | 2010-01-21 | 2013-08-08 | The Regents Of The University Of Californa | Use of human erythrocytes for prevention and treatment of cancer dissemination and growth |
EP2533816A1 (en) | 2010-02-08 | 2012-12-19 | Piramal Imaging SA | F18-tyrosine derivatives for imaging bone metastases |
WO2011127056A2 (en) | 2010-04-05 | 2011-10-13 | The Uab Research Foundation | Biomarkers for assessing exposure to ionizing radiation and absorbed dose |
WO2012166055A1 (en) | 2011-05-31 | 2012-12-06 | Singapore Health Services Pte. Ltd. | Method for detecting disease biomarkers |
GB201116767D0 (en) | 2011-09-28 | 2011-11-09 | St George S Hospital Medical School | Treatment for mitrochondrial neurogastrointestinal encephalomyopathy |
CN104394884A (en) | 2012-03-21 | 2015-03-04 | 爱瑞泰克药物公司 | Medicament for the treatment of acute myeloid leukemia (AML) |
HU230341B1 (en) * | 2012-04-20 | 2016-02-29 | Advancell Diagnosztika Kft. | Quantitative biomarkers of the erythrocyte membrane |
US10883119B2 (en) | 2012-07-11 | 2021-01-05 | Sangamo Therapeutics, Inc. | Methods and compositions for delivery of biologics |
EP4338803A2 (en) | 2013-05-10 | 2024-03-20 | EryDel S.p.A. | Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes |
JP6383920B2 (en) | 2013-09-11 | 2018-09-05 | 有限会社ピコデバイス | Methods used as criteria for Parkinson's disease |
EP3130668B1 (en) | 2014-04-07 | 2019-07-17 | IUCF-HYU (Industry-University Cooperation Foundation Hanyang University) | In-vitro expansion of erythroid cells |
CA2985799A1 (en) | 2015-05-18 | 2016-11-24 | New Health Sciences, Inc. | Methods for the storage of whole blood, and compositions thereof |
CN108883133A (en) | 2015-12-22 | 2018-11-23 | 善威生物私人有限公司 | Use the treatment method of red blood cell |
AU2017379367B2 (en) | 2016-12-20 | 2023-12-07 | Sangui Bio Pty. Ltd | Blood profiling with protease inhibitors |
-
2016
- 2016-10-06 EP EP21207712.7A patent/EP4009047A1/en active Pending
- 2016-10-06 CN CN202111208795.1A patent/CN114019171A/en active Pending
- 2016-10-06 KR KR1020187012951A patent/KR102632490B1/en active IP Right Grant
- 2016-10-06 WO PCT/AU2016/000341 patent/WO2017059477A1/en active Application Filing
- 2016-10-06 US US15/765,963 patent/US11243218B2/en active Active
- 2016-10-06 AU AU2016334875A patent/AU2016334875B2/en active Active
- 2016-10-06 CN CN201680071446.0A patent/CN108700565B/en active Active
- 2016-10-06 JP JP2018537693A patent/JP6824994B2/en active Active
- 2016-10-06 CA CA3001154A patent/CA3001154C/en active Active
- 2016-10-06 EP EP16852887.5A patent/EP3359962B1/en active Active
- 2016-10-06 SG SG11201802754XA patent/SG11201802754XA/en unknown
-
2019
- 2019-01-17 HK HK19100786.7A patent/HK1258470A1/en unknown
-
2021
- 2021-01-13 JP JP2021003537A patent/JP2021073453A/en active Pending
-
2023
- 2023-03-07 JP JP2023034247A patent/JP2023078210A/en active Pending
- 2023-11-13 US US17/845,451 patent/US20240060997A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20180083853A (en) | 2018-07-23 |
CA3001154A1 (en) | 2017-04-13 |
JP6824994B2 (en) | 2021-02-03 |
CN108700565B (en) | 2021-10-29 |
EP4009047A1 (en) | 2022-06-08 |
AU2016334875A8 (en) | 2018-05-10 |
EP3359962A4 (en) | 2019-03-06 |
AU2016334875A1 (en) | 2018-04-26 |
CA3001154C (en) | 2023-10-17 |
EP3359962A1 (en) | 2018-08-15 |
AU2016334875B2 (en) | 2022-10-27 |
JP2018530766A (en) | 2018-10-18 |
JP2023078210A (en) | 2023-06-06 |
US11243218B2 (en) | 2022-02-08 |
EP3359962B1 (en) | 2021-11-17 |
KR102632490B1 (en) | 2024-02-02 |
JP2021073453A (en) | 2021-05-13 |
CN108700565A (en) | 2018-10-23 |
WO2017059477A1 (en) | 2017-04-13 |
US20180306817A1 (en) | 2018-10-25 |
US20240060997A1 (en) | 2024-02-22 |
CN114019171A (en) | 2022-02-08 |
HK1258470A1 (en) | 2019-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL258931A (en) | Therapeutic compounds and methods | |
HK1247614A1 (en) | Therapeutic compounds and uses thereof | |
SG10201913800UA (en) | Patient interfaces | |
SG11201707816PA (en) | Patient interface and aspects thereof | |
ZA201708081B (en) | Preparation comprising arabinoxylo-oligosaccharides | |
HK1258470A1 (en) | Blood preparation and profiling | |
HK1248697A1 (en) | Therapeutic compounds and uses thereof | |
GB2543540B (en) | Decellularising tissue | |
ZA201802256B (en) | Compounds and therapeutic uses thereof | |
PL3398598T3 (en) | Sulfonamide derivative and preparation method and use thereof | |
GB201502412D0 (en) | Therapeutic use | |
HK1256368A1 (en) | Calicheamicin-antibody-drug conjugates and methods of use | |
PT3308781T (en) | Blood pressure-lowering agent | |
GB201504915D0 (en) | Ophthalmoscope | |
ZA201801134B (en) | Hydroxytriazine compound and medical use thereof | |
HK1244684A1 (en) | Keratin treatments | |
GB201515194D0 (en) | Nappy and insert therefor | |
HRP20200115T1 (en) | Medical plaster | |
GB201506786D0 (en) | Therapeutic use | |
HRP20182167T1 (en) | Benzylhydroxyde derivatives, preparation thereof and therapeutic use thereof | |
IL258592A (en) | Morphinan derivative and medical usage thereof | |
AU2015904075A0 (en) | Blood preparation and profiling | |
GB2545167B (en) | Cloches and use thereof | |
GB201514770D0 (en) | Compounds and their use | |
GB201504770D0 (en) | Medical devices and methods |